Lavior Science

FROM PLANT TO SKIN

We own the research, development and production process from start to finish. We cultivate our own unique organic chemotype of Inula viscosa, the richest and most potent of this plant species. Governed by stringent protocol, the initial planting, growing and cultivation stages are strictly monitored - harvesting to packaging.

INNOVATIVE FORMULA

Our breakthrough proprietary formula combines revolutionary scientific advancements with leading medicinal properties. Lavior has extracted active ingredients with anti-inflammatory, antiviral, antibacterial, antimicrobial, antifungal and antioxidant properties from botanicals to engineer cutting-edge medical treatments.

SCIENCE AT ITS BEST

With cultivated precision, LAVIOR's R&D team of researchers, agronomists, chemists, dermatologists and other medical professionals have created products which answer the needs of specific skin conditions and trigger the immune system to speed up the healing process.

MECHANISM OF ACTION

Lavior’s Proprietary Technology targets NFkB, STAT1 and COX-2 Pathways for Effective Treatment of Wounds and Inflammatory Conditions.

Mechanism of Action for Effective Management
of Wounds and Inflammatory Conditions:
  • Reduces both NFkB and STAT1 protein level which leads to proteasomal degradation
  • Reduces NFκB expression: regulates fewer secretion of the pro-inflammatory cytokines
  • COX-2 inhibitor: directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain
  • Triggers the immune system to subvert bacterial blocking and speed up healing
Clinical Study : 4-week predictive marker study*

LAVIOR Inc. conducted clinical trials in a well-respected hospital under the IRB of the New York College of Podiatric Medicine. The trials were a phenomenal success, showing positive results in all participating patients.

Most of the wounds had healed completely after 4 weeks, and the remainder by 6 weeks. The existing clinical trials and the company successful cases among end users and physicians showed significant results in accelerating the wound healing process in large surface wounds

Results

The study showed that LAVIOR wound dressing reduced the size of the ulcer area by an average of 83.3% versus 30% with the control group, in just 4 weeks.

2022 Hospital Use Case

In less than three months, and after seeing significant improvement in all of the patients treated with LAVIOR, the wound care center now treats close to 150 patients with LAVIOR products. LAVIOR is currently THE NEW STANDARD OF CARE in this Wound Care Center.

LAVIOR was able to reduce the cost of wound care routines, treating patients with advanced-stage wounds with ONE SINGLE PRODUCT.